CVX-51401(CVX-51401) - 药物靶点：caveolin_在研适应症：黄斑变性，葡萄膜炎_专利_临床

概要

基本信息

药物类型

合成多肽

别名

靶点

caveolin

作用机制

caveolin调节剂(Caveolin蛋白调节剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

Yale School of MedicineCavtherx, Inc.

Trefoil Therapeutics, Inc.初创企业

非在研机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

100 项与 CVX-51401 相关的临床结果

登录后查看更多信息

100 项与 CVX-51401 相关的转化医学

登录后查看更多信息

100 项与 CVX-51401 相关的专利（医药）

登录后查看更多信息

1

项与 CVX-51401 相关的文献（医药）

2021-05-14·Translational Vision Science & Technology3区 · 医学

Characterization of a Novel Caveolin Modulator That Reduces Vascular Permeability and Ocular Inflammation

3区 · 医学

ArticleOA

作者: Eveleth, David ; Bernatchez, Pascal N. ; Tao, Bo ; Bradshaw, Ralph A. ; Sessa, William C.

PurposeCaveolin (Cav) regulates various aspect of endothelial cell signaling and cell-permeable peptides (CPPs) fused to domains of Cav can reduce retinal damage and inflammation in vivo. Thus, the goal of the present study was to identify a novel CPP that improves delivery of a truncated Cav modulator in vitro and in vivo.MethodsPhage display technology was used to identify a small peptide (RRPPR) that was internalized into endothelial cells. Fusions of Cav with the peptide were compared to existing molecules in three distinct assays, vascular endothelial growth factor-A (VEGF) induced nitric oxide (NO) release, VEGF induced vascular leakage, and in a model of immune mediated uveitis.ResultsRRPPR was internalized efficiently and was potent in blocking NO release. Fusing RRPPR with a minimal Cav inhibitory domain (CVX51401) dose-dependently blocked NO release, VEGF induced permeability, and retinal damage in a model of uveitis.ConclusionsCVX51401 is a novel Cav modulator that reduces VEGF and immune mediated inflammation.Translational RelevanceCVX51401 is an optimized Cav modulator that reduces vascular permeability and ocular inflammation that is poised for clinical development.

100 项与 CVX-51401 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
湿性年龄相关性黄斑变性	临床1期	美国	Cavtherx, Inc.	2021-12-28
黄斑变性	临床前	美国	Yale School of Medicine	2021-05-14
黄斑变性	临床前	美国	Trefoil Therapeutics, Inc.初创企业	2021-05-14
葡萄膜炎	临床前	美国	Trefoil Therapeutics, Inc.初创企业	2021-05-14
葡萄膜炎	临床前	美国	Yale School of Medicine	2021-05-14
葡萄膜炎	临床前	美国	Cavtherx, Inc.	2021-05-14